Clinical Research
Cardiovascular Disease and Risk
N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study

https://doi.org/10.1016/j.jacc.2006.08.052Get rights and content
Under an Elsevier user license
open archive

Objectives

We sought to assess the ability of N-terminal pro-B-type natriuretic peptide (N-BNP) to predict vascular events in high-risk people and to test whether statins benefit people with high levels of N-BNP.

Background

The predictive value of N-BNP for occlusive vascular events and the effects of statins in people with high N-BNP levels are uncertain.

Methods

A total of 20,536 people were assigned randomly to simvastatin 40 mg daily or placebo for an average of 5 years. Five baseline N-BNP groups were defined (<386; 386 to 1,171; 1,172 to 2,617; 2,618 to 5,758; and ≥5,759 pg/ml).

Results

Baseline N-BNP was strongly predictive of future vascular events independently of other characteristics. Compared with participants with N-BNP <386 pg/ml, those with levels ≥5,759 pg/ml had adjusted relative risks for major vascular events (MVEs) (i.e., major coronary events [MCE] [nonfatal myocardial infarction or coronary death], stroke, or revascularization) of 2.26, for MCE of 3.09, for stroke of 1.80, and for heart failure (hospitalization or death) of 9.23 (all p < 0.0001). Overall, simvastatin allocation reduced the relative risk of MVE by 24% (95% confidence interval 19 to 28). There was a trend toward smaller (but still significant) proportional reductions in MVE among participants with greater baseline N-BNP levels, but the absolute benefits of simvastatin allocation were similar at all N-BNP levels. Simvastatin allocation was also associated with a 14% (95% confidence interval 0 to 25) proportional reduction in heart failure. No excess risk of other vascular and nonvascular outcomes was observed with simvastatin allocation among participants with greater baseline values of N-BNP.

Conclusions

In this study, N-BNP levels were strongly predictive not only of heart failure but also of MVEs. In people with high N-BNP levels consistent with heart failure, statin allocation significantly reduced vascular risk, with no evidence of hazard. (Heart Protection Study; http://www.controlledtrials.com/ISRCTN48489393/48489393)

Abbreviations and Acronyms

BNP
brain-type natriuretic peptide
CI
confidence interval
LDL
low-density lipoprotein
LVEF
left ventricular ejection fraction
MCE
major coronary event
MI
myocardial infarction
MVE
major vascular event
N-BNP
N-terminal pro-B-type natriuretic peptide

Cited by (0)

Please see the Appendixfor a full list of members of the Heart Protection Study Collaborative Group Writing Committee. The MRC/BHF Heart Protection Study was funded by the U.K. Medical Research Council, the British Heart Foundation, Merck & Co., and Roche Vitamins Ltd. Both the Clinical Trial Service Unit and all members of the Writing Committee (see Appendix) have a policy of not accepting honoraria or other payments from the pharmaceutical industry, except for the reimbursement of costs to participate in scientific meetings.

1

[email protected].